Skip to main content
OpenTrials

Clinical trial condition

Metastatic Gastroesophageal Junction Adenocarcinoma

Explore clinical trials studying Metastatic Gastroesophageal Junction Adenocarcinoma. Study availability and eligibility vary by location and protocol.

24 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Gastroesophageal Junction Adenocarcinoma trial results

Completed

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

NCT03008278

Conditions
Digestive System Diseases, Digestive System Neoplasms, Esophageal Diseases, +21 more
Locations
  • City of Hope Corona Corona, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope Antelope Valley Lancaster, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 32 locations
View Trial Details
Completed

IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

NCT03918499

Conditions
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, +15 more
Locations
  • HonorHealth Research Institute Scottsdale, Arizona, United States
  • City of Hope Medical Center Duarte, California, United States
  • Texas Oncology at Baylor Charles A Sammons Cancer Center Dallas, Texas, United States
View Trial Details
Active, Not Recruiting

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

NCT03641313

Conditions
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, +5 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
View all 31 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

NCT04535401

Conditions
Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma, +24 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri, United States
View Trial Details
Active, Not Recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

NCT01142388

Conditions
Adenocarcinoma Of Esophagus, Carcinoma, Carcinoma, Squamous Cell, +21 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
  • The Medical Center of Aurora Aurora, Colorado, United States
  • Boulder Community Foothills Hospital Boulder, Colorado, United States
View all 232 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

NCT04460937

Conditions
Adenocarcinoma Of Esophagus, Brain Diseases, Brain Neoplasms, +80 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Northwestern University Chicago, Illinois, United States
  • University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details
Active, Not Recruiting

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Conditions
Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, +80 more
Locations
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
View all 23 locations
View Trial Details

Related conditions